about
Melt analysis of mismatch amplification mutation assays (Melt-MAMA): a functional study of a cost-effective SNP genotyping assay in bacterial modelsIndividualized medicine enabled by genomics in Saudi ArabiaHarvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactomePharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision MedicineGene expression variability in human hepatic drug metabolizing enzymes and transportersGenome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in EuropeImpact of genetic variation on three dimensional structure and function of proteins.Pharmacogenomic and clinical data link non-pharmacokinetic metabolic dysregulation to drug side effect pathogenesisDigital detection of genetic mutations using SPC-sequencing.Data-driven methods to discover molecular determinants of serious adverse drug events.Phenobarbital for the treatment of epilepsy in the 21st century: a critical review.Genetic factors in the predisposition to drug-induced hypersensitivity reactionsCYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.The pharmacogenomics of HIV therapy.Ethical perspectives on pharmacogenomic profiling in the drug development process.Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy.Adverse drug reactions: back to the futureThe application of functional genomics to Alzheimer's disease.Genetic predisposition to oxcarbazepine induced Stevens-Johnson syndrome.Independent and combined effects of environmental factors and CYP2C19 polymorphisms on the risk of esophageal squamous cell carcinoma in Fujian Province of China.Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenalPharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.Integrating pharmacogenetics into society: in search of a model.Databases in the area of pharmacogenetics.Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug eventsMolecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions.Role of metabolism in drug-induced idiosyncratic hepatotoxicity.Allergic reactions to beta-lactams.The emerging importance of DNA mapping and other comprehensive screening techniques, as tools to identify new drug targets and as a means of (cancer) therapy personalisation.Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactionsAggravation of epilepsy by anti-epileptic drugs.The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects.Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology.Personalized medicine and the clinical laboratory.Relationships Among Adverse Events, Disease Characteristics, and Demographics in Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin.Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.Functional polymorphisms in the CYP2C19 gene contribute to digestive system cancer risk: evidence from 11,042 subjects.CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factorsClozapine-induced agranulocytosis and its genetic determinants.
P2860
Q21134738-AC7DA90E-3502-4DCE-B5D8-F303355243F1Q26861059-08EB7713-A492-48A7-AB88-37F918927053Q27335598-2492B4EB-F53C-4E7C-B59E-67BA084837ACQ27692687-61AC62EA-2240-4BEF-AE06-B7D18BFD406DQ28486732-F1F487EE-3628-45C5-8E9E-F3FE43147653Q28943413-980A4D74-0F15-46A3-9BC9-5A2FFBE7783CQ30491136-88495F2E-F2B9-42EC-8129-B617F3AFC20EQ30968128-70DE0481-85C6-4A6A-82FE-7B8EB9139DD0Q33197458-586C8E97-E4F0-478A-9ACC-78E3C95BAB6FQ33403734-2C428693-E9DF-496D-BFA6-7542C2B0F97DQ34343308-C4935B2A-C66A-4556-A7CA-CAF023337D3FQ34508545-B6BA3E2F-7EA4-4C65-A88F-FAA97B8F912DQ34564302-755937D9-1EF0-4A09-88E2-B6FDE7D7674DQ34574033-58803AA7-F55F-4F53-BAD6-14172016A8B3Q34743306-CA89972D-3D1E-4389-8872-87D734708BD7Q35127790-B782B71E-8EB0-49FE-AC07-882F5447BFB4Q35130832-748B005F-7021-4266-9FAA-6B1180EF2D1DQ35207554-38E3C5AF-5DCE-4F5D-B09D-AC4C5D99E68CQ35307084-6FC23E12-1D80-4E40-9021-E6990E973816Q35576753-D0E7F6B5-30A4-4C68-B288-76ED2FDAB8B2Q35814091-777FB0BE-4DBC-4165-93E7-2DAB8ED15B45Q35840905-95AB09FB-3BD9-4142-AEC8-629FC26F1226Q35873680-CA5B5078-9165-4A96-87EC-A598E35DAB92Q35889615-290F314E-8FC9-4C80-9416-1BD60EC1B2ABQ35959328-37AD679E-3C9D-4DD7-A9B9-31BD9D27A6DCQ35988128-D308A9C9-1F4F-4735-8A02-9CDDF0D8C330Q36089652-4ECFA518-D36E-4B73-BEBE-67FEB1D593FCQ36179528-5B116C0E-5AE9-4BEF-8BAC-1CB627F38B01Q36349723-3B6B1BDD-ABCE-4B60-8CE9-0C9F5282AE72Q36425978-6E470E48-60E0-423F-888B-0BB5A8AE305CQ36439171-099FFE45-973B-4E38-A50D-DDE47B394BB1Q36445616-E2AFA093-6DE5-460F-A1E2-E10D8C23F073Q36475111-D283B738-12EC-4CB7-9557-005B665C739AQ36811537-0D7E8AFB-C049-4F56-8F3D-D9DDAA103C0EQ36916966-7CDF1140-657E-4A59-A677-BD7C973D9400Q36973380-62C80CD4-DFCA-4CD1-BC86-073E7402CC09Q36986507-874F2ABC-747F-440A-9093-092447F87F78Q37017860-2B1B6980-E05F-4207-9A3A-217F5D1DC107Q37140633-86872545-6AF2-4480-BEF1-5B35F129631CQ37235641-674752C9-A25F-4BE4-A017-6ABAB27993D8
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Genetic susceptibility to adverse drug reactions.
@ast
Genetic susceptibility to adverse drug reactions.
@en
Genetic susceptibility to adverse drug reactions.
@nl
type
label
Genetic susceptibility to adverse drug reactions.
@ast
Genetic susceptibility to adverse drug reactions.
@en
Genetic susceptibility to adverse drug reactions.
@nl
prefLabel
Genetic susceptibility to adverse drug reactions.
@ast
Genetic susceptibility to adverse drug reactions.
@en
Genetic susceptibility to adverse drug reactions.
@nl
P1476
Genetic susceptibility to adverse drug reactions.
@en
P2093
P304
P356
10.1016/S0165-6147(00)01717-X
P577
2001-06-01T00:00:00Z